Clinical trial
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
NCT00393107 · Gruppo Italiano Studio Linfomi, Other · Completed
Key facts
| NCT number | NCT00393107 |
|---|---|
| Title | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab |
| Official title | Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma |
| Lead sponsor | Gruppo Italiano Studio Linfomi, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Follicular Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab, fludarabine, cyclophosphamide |
| Enrollment | 54 |
| Start date | Mar 1, 2000 |
| Completion | Aug 1, 2006 |
| First posted | Oct 26, 2006 |
| Last update posted | Oct 26, 2006 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: